NCT00044187View on ClinicalTrials.gov

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

PHASE4CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

September 30, 2003

Conditions

SchizophreniaPsychotic DisordersBipolar Disorder

Interventions

DRUG

Sibutramine

Trial Locations (16)

Unknown

El Centro

Jacksonville

Miami

Boise

Chicago

Indianapolis

Lafayette

Prairie Village

Milford

Clementon

Beachwood

Johnson City

Memphis

Houston

Richmond

Bellevue

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00044187 - The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder | Biotech Hunter | Biotech Hunter